DLL3 and small cell lung carcinoma: Tarlatamab, a half-life extended BiTE targeting delta-like protein 3 (DLL3) and CD3, has demonstrated manageable safety and durable responses in heavily pretreated patients with SCLC in a phase I trial [11].